Pemigatinib – Selective FGFR1/2/3 Tyrosine Kinase Inhibitor

Pemigatinib is an oral, potent, small-molecule targeted inhibitor of fibroblast growth factor receptor (FGFR) types 1, 2, and 3. The drug was developed for the highly selective therapy of advanced stages of malignancies, specifically locally advanced or metastatic cholangiocarcinoma (bile duct cancer) harboring confirmed FGFR2 gene fusions or other rearrangements. The mechanism of action of pemigatinib involves competitive binding to the ATP-dependent domains of FGFR receptors, effectively blocking their transphosphorylation and interrupting downstream intracellular signaling cascades (including the MAPK and PI3K/AKT pathways). This results in powerful suppression of tumor cell proliferation, migration, and survival, as well as the inhibition of neoangiogenesis within the neoplastic tissue.

The clinical uniqueness of pemigatinib lies in its role as a precision medicine agent within personalized oncology. Prior to its introduction, patients with chemoresistant cholangiocarcinoma faced extremely limited therapeutic options, whereas targeted blockade of aberrant FGFR2 signaling yields durable objective responses. The drug also exhibits selective activity against FGFR3, expanding its therapeutic potential into other solid tumors (e.g., urothelial carcinoma). Pemigatinib is characterized by linear pharmacokinetics, is rapidly absorbed following oral administration, is metabolized primarily in the liver by the CYP3A4 isoenzyme, and is excreted predominantly in the feces.

The drug is administered orally. Prior to initiating therapy, confirmation of FGFR2 gene rearrangements using validated molecular-genetic methods is mandatory, and regular monitoring of serum phosphate levels is required throughout the course.

Wikipedia page
Pemigatinib

Indications

Pemigatinib is indicated for the targeted treatment of adult patients with the following oncological conditions:

  • Cholangiocarcinoma: treatment of recurrent, locally advanced, or metastatic cholangiocarcinoma (intrahepatic bile duct cancer) in adult patients with a confirmed FGFR2 fusion or other rearrangement that has progressed after at least one prior line of systemic chemotherapy.
  • Myeloid/Lymphoid Neoplasms: treatment of adult patients with relapsed or refractory myeloid or lymphoid neoplasms with FGFR1 gene rearrangements.

Dosage and administration

The dosing regimen of pemigatinib is based on a cyclic schedule designed to balance potent antitumor efficacy with the management of class-specific toxicities.

  • Standard Dose: the recommended therapeutic dose is 13.5 mg taken orally once daily.
  • Cycle Schedule: the drug is taken daily for 14 consecutive days (2 weeks), followed by a mandatory 7-day rest period (1 week) without treatment. A full cycle constitutes 28 days.
  • Administration Method: tablets are swallowed whole at approximately the same time each day, with or without food, with a glass of water. Do not crush, split, or chew the tablets.
  • Missed Dose: if a dose is missed by more than 4 hours, the patient should skip the missed dose and resume the regular schedule the following day. If vomiting occurs after administration, an additional dose should not be taken.
  • Management of Hyperphosphatemia: if serum phosphorus levels exceed 5.5 mg/dL, a low-phosphate diet and phosphate-lowering therapy should be initiated. If levels exceed 7.5 mg/dL, the pemigatinib dose should be temporarily reduced to 9 mg or withheld.

The use of pemigatinib is restricted by specific risk factors and is contraindicated in the following conditions:

  • Hypersensitivity: confirmed allergic reaction or individual hypersensitivity to pemigatinib or any of the inactive pharmaceutical excipients.
  • Ophthalmic Risks: presence of active or uncompensated serous retinal detachment or retinal pigment epithelial detachment (due to the high risk of exacerbation).
  • Pregnancy and Lactation: the drug carries significant embryotoxic and teratogenic potential and can cause fetal harm. Pregnancy during treatment is strictly forbidden. Breastfeeding must be discontinued during therapy and for 1 week following the final dose.
  • Drug Interactions: concomitant intake of grapefruit juice or strong CYP3A4 inducers or inhibitors is contraindicated, as they unpredictably alter the plasma concentration of the drug.

The side effects of pemigatinib are characteristic of FGFR pathway inhibitors and predominantly involve electrolyte imbalances and alterations in ectodermal tissues:

  • Metabolic Disorders: hyperphosphatemia (the most frequent dose-dependent effect, resulting from FGFR blockade in renal tubules), and less commonly, hypophosphatemia.
  • Ophthalmologic Effects: development of dry eye syndrome, blurred vision, trichiasis, and specific serous retinal pigment epithelial detachment (RPED).
  • Dermatological Reactions: pronounced alopecia (hair loss), dry skin, palmar-plantar erythrodysesthesia syndrome, onycholysis (brittle or detached nails), and pruritus.
  • Digestive Tract: stomatitis (oral inflammation), dysgeusia (taste alterations), dry mouth, nausea, and diarrhea.
  • General Symptoms: pronounced asthenia, fatigue, arthralgia (joint pain), and an increased susceptibility to urinary tract infections.

Frequently Asked Questions

Pemigatinib is an oral targeted therapy that functions as a potent and selective inhibitor of fibroblast growth factor receptor (FGFR) types 1, 2, and 3 ($FGFR1, FGFR2, FGFR3$). In certain cancer cells, alterations or overactivity in these receptors drive uncontrolled cellular division and survival. Pemigatinib binds to FGFR and blocks downstream intracellular signaling cascades, thereby halting tumor progression and inducing malignant cell death.
Pemigatinib is indicated for two primary therapeutic avenues. First, for the treatment of adults with previously treated, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) harboring a confirmed $FGFR2$ fusion or rearrangement. Second, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with an $FGFR1$ gene rearrangement. Genetic testing to confirm these biomarkers is mandatory before initiating therapy.
Pemigatinib is administered in an intermittent cyclic regimen: tablets are taken once daily for 14 consecutive days (2 weeks), followed by a 7-day break (1 week) without the drug. This establishes a complete 21-day cycle. The tablets should be taken at the same time each day, with or without food, and must be swallowed strictly whole. During treatment, consuming grapefruit or grapefruit juice is prohibited, as it can dangerously elevate drug levels in the blood.
An increase in blood phosphate levels (hyperphosphatemia) is the most common and anticipated class-effect of pemigatinib, resulting from the inhibition of the FGFR pathway, which plays a role in renal phosphate clearance. Your physician will regularly monitor blood phosphorus levels. Management typically includes a low-phosphate diet and, if established thresholds are exceeded, the initiation of phosphate-lowering therapies (phosphate binders).
Pemigatinib can cause significant ocular disorders, including dry eye, keratitis, and retinal pigment epithelial detachment (RPED), which can lead to blurred vision or visual impairment. A comprehensive ophthalmological examination (including optical coherence tomography - OCT) is required prior to starting therapy, periodically during the first months of treatment, and immediately if any visual changes (such as flashes of light, floaters, or blurry vision) occur.

List of medicines by active substance

-11%
Pemitinib
View
Everest

Pemitinib

Pemigatinib
13.5 mg 14 tablets
28966₴ 32408₴
✅ All products loaded (1)
Unifarm

Unifarm app

Safari → Share → Add to Home Screen Firefox: menu ⋮ → Install or Add to Home screen. If missing, open the site in Chrome. Chrome: menu ⋮ → Install app or Add to Home screen.

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00